In this annual review, we include all drugs in development by pharmaceutical companies, from those at the preclinical stage, through the various stages of clinical testing and regulatory approval, and up to and including launch. Launched drugs are counted, but only if they are still in development for additional indications or markets. Drugs whose development has been terminated, or is complete, are not included.
Business in China is going through a period of uncertainty.
Related products
